RÉSUMÉ
This study explored the effects of GnRH agonist [GnRHa] immunity on expression of FSHR mRNA in pituitary and FSHR protein in uteri, and also confirmed its efficacy on uterine development. 42 prepuberty and non cyclic ewes were assigned to 6 experimental groups [EG] during anestrus season. Animals in EG-I, EG-II and EG-III were subcutaneously injected with 200, 300 and 400 ìg alarelin antigens [day 0 and 14]. Animals in EG-IV and EG-V were subcutaneously injected with 200 and 300 microg alarelin antigen [day 0, 7, 14 and 21]. Uterine FSHR protein expression was detected using Western-blotting. RT-PCR was implemented to measure expression of pituitary FSHR mRNA on day 70 after the immunity. Compared to the CG, pituitary FSHR mRNA levels reduced by 58%, 88% and 91% [P<0.01] in EG-I, EG-II and EG-III. FSHR mRNA in EG-IV and EG-V reduced by 64.29% [P<0.05] and 10.11% compared to EG-I and EG-II. Expression levels of uterine FSHR protein in EG-III and EG-V were higher than that in CG. The uterine gl and s, mitochondriaandmitochondrial crista decreased, and the gl and ular cavity reduced, also the microvilli shortened. Uterine horn weights in EG-I, EG-II and EG-III reduced by 4.66%, 10.20% and 16.63%, respectively. Uterine wall thickness [UWT] in EG-I, EG-II and EG-III reduced by 1.41%, 5.84% and 8.75% [P<0.05]. The endometrial epithelium thickness [EET] in EG-I, EG-II and EG-III decreased 2.70%, 8.87% and 19.15%. The positive correlations between uterine horn weights and UWT, EET and FSHR were calculated